{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T04:54:41Z","timestamp":1795236881832,"version":"4.10.3"},"reference-count":31,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor\u2013naive patients with mIDH1R132 relapsed\/refractory (R\/R) acute myeloid leukemia (AML) received olutasidenib monotherapy 150\u00a0mg twice daily in the pivotal cohort of this study. The median age of participants was 71 years (range, 32-87 years) and the median number of prior regimens received by patients was 2 (1-7). The rate of complete remission (CR) plus CR with partial hematologic recovery (CRh) was 35%, and the overall response rate was 48%. Response rates were similar in patients who had, and who had not, received prior venetoclax. With 55% of patients censored at the time of data cut-off, the median duration of CR\/CRh was 25.9\u00a0months. The median duration of overall response was 11.7\u00a0months, and the median overall survival was 11.6\u00a0months. Of 86 patients who were transfusion dependent at baseline, a 56-day transfusion independence was achieved in 29 (34%), which included patients in all response groups. Grade 3 or 4 treatment-emergent adverse events (\u226510%) were febrile neutropenia and anemia (n\u00a0= 31; 20% each), thrombocytopenia (n\u00a0= 25; 16%), and neutropenia (n\u00a0= 20; 13%). Differentiation syndrome adverse events of special interest occurred in 22 (14%) patients, with 14 (9%) grade \u22653 and 1 fatal case reported. Overall, olutasidenib induced durable remissions and transfusion independence with a well-characterized and manageable side effect profile. The observed efficacy represents a therapeutic advance in this molecularly defined, poor-prognostic population of patients with mIDH1 R\/R AML. This trial was registered at www.clinicaltrials.gov as #NCT02719574.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009411","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T22:35:53Z","timestamp":1675290953000},"page":"3117-3127","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":140,"title":["Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory <i>IDH1<\/i>-mutated AML"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"St\u00e9phane","family":"de Botton","sequence":"first","affiliation":[{"name":"1Hematologie Clinique, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"2D\u00e9partement (DMU) d\u2019h\u00e9matologie et immunologie, APHP Nord, Service d'h\u00e9matologie s\u00e9niors, H\u00f4pital St Louis\/universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-9952","authenticated-orcid":false,"given":"Karen","family":"Yee","sequence":"additional","affiliation":[{"name":"3Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"4Service d\u2019h\u00e9matologie, CHU de Toulouse, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"5The Alfred Hospital and Monash University, Peter Mac Callum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"6Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Taussig","sequence":"additional","affiliation":[{"name":"7Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[{"name":"8Service d\u2019H\u00e9matologie Clinique et Th\u00e9rapie Cellulaire, CHU Bordeaux, Universit\u00e9 de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Braun","sequence":"additional","affiliation":[{"name":"9Service d'H\u00e9matologie Clinique H\u00f4pital Avicenne-APHP-Universit\u00e9 Paris XIII, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-6049","authenticated-orcid":false,"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[{"name":"10IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology Ser\u00e0gnoli, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-9893","authenticated-orcid":false,"given":"Carolyn","family":"Grove","sequence":"additional","affiliation":[{"name":"11PathWest & Sir Charles Gairdner Hospital, Nedlands, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-5809","authenticated-orcid":false,"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[{"name":"12University of California Davis School of Medicine, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Khwaja","sequence":"additional","affiliation":[{"name":"13University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Legrand","sequence":"additional","affiliation":[{"name":"14H\u00f4pital Saint-Antoine, Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[{"name":"15Service d'h\u00e9matologie clinique, Nantes University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[{"name":"16Institut Catal\u00e0 d'Oncologia, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Blum","sequence":"additional","affiliation":[{"name":"17Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6346-4791","authenticated-orcid":false,"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[{"name":"18Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra K.","family":"Hiwase","sequence":"additional","affiliation":[{"name":"19Royal Adelaide Hospital and SA Pathology, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Jurcic","sequence":"additional","affiliation":[{"name":"20Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauter","sequence":"additional","affiliation":[{"name":"21Braunschweig Municipal Hospital, Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2404","authenticated-orcid":false,"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[{"name":"22Lyon-Sud Hospital, Pierre-B\u00e9nite, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Watts","sequence":"additional","affiliation":[{"name":"23University of Miami Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[{"name":"24Karmanos Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Polyanskaya","sequence":"additional","affiliation":[{"name":"25Forma Therapeutics, Inc, Watertown, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Brevard","sequence":"additional","affiliation":[{"name":"25Forma Therapeutics, Inc, Watertown, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sweeney","sequence":"additional","affiliation":[{"name":"25Forma Therapeutics, Inc, Watertown, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Barrett","sequence":"additional","affiliation":[{"name":"25Forma Therapeutics, Inc, Watertown, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"26Georgia Cancer Center, Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"s1","key":"2023071017083114000_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/01.HS9.0000562500.21650.32","article-title":"PS1051 FT-2102, an IDH1\u00a0m inhibitor, induces mutation clearance in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) treated in phase 1 dose escalation and expansion study","volume":"3","author":"Botton","year":"2019","journal-title":"HemaSphere"},{"issue":"8","key":"2023071017083114000_bib2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"2023071017083114000_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"2023071017083114000_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov"},{"issue":"6127","key":"2023071017083114000_bib5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"issue":"7390","key":"2023071017083114000_bib6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"25","key":"2023071017083114000_bib7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023071017083114000_bib8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1182\/blood.V126.23.1310.1310","article-title":"Longitudinal pharmacokinetic\/pharmacodynamic profile of AG-120, a potent inhibitor of the IDH1 mutant protein, in a phase 1 study of IDH1-mutant advanced hematologic malignancies","volume":"126","author":"Fan","year":"2015","journal-title":"Blood"},{"issue":"15 suppl","key":"2023071017083114000_bib9","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2020.38.15_suppl.2505","article-title":"A\u00a0phase Ib\/II study of olutasidenib in patients with relapsed\/refractory IDH1 mutant gliomas: safety and efficacy as single agent and in combination with azacitidine","volume":"38","author":"De La Fuente","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"2023071017083114000_bib10","author":"Lowery","year":"2017"},{"issue":"11","key":"2023071017083114000_bib11","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023071017083114000_bib12","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023071017083114000_bib13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","article-title":"Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor","volume":"63","author":"Caravella","year":"2020","journal-title":"J\u00a0Med Chem"},{"issue":"24","key":"2023071017083114000_bib14","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards of therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023071017083114000_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"2023071017083114000_bib16","author":"de Botton","year":"2015"},{"key":"2023071017083114000_bib17","author":"de la Fuente","year":"2019"},{"key":"2023071017083114000_bib18","author":"Fan","year":"2015"},{"key":"2023071017083114000_bib19","author":"Mellinghoff","year":"2018"},{"key":"2023071017083114000_bib20","author":"Mellinghoff","year":"2017"},{"issue":"18","key":"2023071017083114000_bib21","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023071017083114000_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"2023071017083114000_bib23","unstructured":"IDHIFA [enasidenib]\n          . Prescribing information. Celgene Corporation, Summit, NJ. Accessed 15 February 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209606s000lbl.pdf."},{"key":"2023071017083114000_bib24","unstructured":"Tibsovo [ivosidenib]\n          . Prescribing information. Servier Pharmaceuticals LLC, Boston, MA. Accessed 15 February 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211192_s008lbl.pdf."},{"key":"2023071017083114000_bib25","unstructured":"US Department of Health and Human Services, Food and Drug Administration\n          . Acute myeloid leukemia: developing drugs and biological products for treatment guidance for industry. Accessed 15 February 2023. https:\/\/www.fda.gov\/media\/162362\/download."},{"issue":"18","key":"2023071017083114000_bib26","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023071017083114000_bib27","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1002\/cncr.27429","article-title":"Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients","volume":"118","author":"Faderl","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"2023071017083114000_bib28","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023071017083114000_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2023071017083114000_bib30","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2023071017083114000_bib31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2021-144905","article-title":"Olutasidenib (FT-2102) in combination with azacitidine induces durable complete remissions in patients with mIDH1 acute myeloid leukemia","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3117\/2062965\/blooda_adv-2022-009411-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3117\/2062965\/blooda_adv-2022-009411-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T17:19:57Z","timestamp":1689009597000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/13\/3117\/494290\/Olutasidenib-FT-2102-induces-durable-complete"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,7,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009411","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}